WHO WE ARE
UK leader focused on the research, cultivation,
manufacturing and supply of breakthrough cannabis-based medicines.
AT A GLANCE
100,000 sq ft UK based GMP approved facility comprising a laboratory and indoor hydroponic grow facility
One of the first licenced by the UK regulators and MHRA to produce GMP high-THC medicinal cannabis
MHRA (conditionally) approved clinical trial evaluating the use of cannabis medicines for the management of chronic pain
First-mover advantage to capture large UK opportunity, in a market with significant barriers to entry
£20 million of funding received to date to support execution of growth strategy
Publicly listed on London Stock Exchange (AIM) and the second pharmaceutical cannabis business on the world’s leading growth market since GW Pharma (acquired for $7bn in 2021)
UK’s leading cannabis cultivation and drug development facility
Celadon has a 100,000 sq ft licenced facility based in the West Midlands in the UK. It is an EU-GMP facility with indoor hydroponic cultivation of high-THC cannabis flower, API extraction and an R&D lab for its drug development programme.
The facility has had substantial investment in it and has involved four years of close cooperation with UK regulators and the MHRA to build to EU-GMP standards and the highest level of security.
The facility is being built in three phases:
Phase 1: completed in 2021 with five indoor cultivation rooms, API extraction and R&D lab.
Phase 2: significant addition of indoor cultivation capacity, aiming to be operational in Q1 2023.
Phase 3: further expansion of cultivation and manufacturing capacity, with work targeted in 2024-25.
At full capacity, the facility could produce around 9 tonnes of product.
Celadon’s mission is to improve quality of life for patients most in need by developing breakthrough cannabis-based medicines
BOARD & MANAGEMENT
CEO & Founder
Chief Financial Officer
Senior Independent NED
Senior Leadership Team
Chief Scientific Officer